Receive The Newest Study Notifications

Canopy Growth Corporation’s (NYSE:CGC) medical division Spectrum Therapeutics has shared an update on the progress of its development and commercialization of validated cannabis medicines through clinical trials. There is an increasing demand for cannabinoid-based...

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, announced the first patient has been enrolled in Part 2 of JX594-REN026, a Phase 1b clinical trial of Pexa-Vec...

NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in refractory chronic cough ~ Findings support further development of...

AXO-Lenti-PD was observed to be generally well tolerated at six months, and continued to demonstrate benefits in both patients across multiple measures after a single administration Totality of data across the program at 6 months supports overall favorable product...

ClinOne, a mobile clinical trial management solution, now provides integration with Uber Health to offer simple transportation services for patients enrolled in clinical trials. ClinicalTrialConnect, ClinOne’s patient-facing concierge platform, manages patients’...

Making it Easier for Pancreatic Cancer Patients to Pursue Clinical Trials  Let's Win! Pancreatic Cancer announces an expanded Clinical Trials section of the website. The enhancements include a dedicated clinical trials matching service for pancreatic cancer patients,...

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe, ILUVIEN is expected to launch in certain EU countries during the second half of 2019 ATLANTA, June 06,...

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with...

Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).  The trial, being...

Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced...

RC48, a novel antibody-drug conjugate (ADC) targeting HER2-positive solid tumours showed a 51% confirmed objective response rate (cORR) Image Courtesy: Enzo Life Science RemeGen, Ltd. announced positive promising results for a Phase II clinical trial of RC48 on 4 June...

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), announced today that Dr. Vimal Mehta, Chief Executive Officer and Founder of BTI, will participate in a panel at the BIO International Convention in Philadelphia, PA. BTI is a clinical-stage...

Duchesnay Inc., a pharmaceutical company specializing in women's health, is pleased to announce the publication of a study showing improvements in vulvovaginal health with ospemifene as assessed by prospective vulvar-vestibular photography and other direct visual...

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies related to the screening efficacy of the EyeArt® AI Eye...

Takeda's Phase 3b head-to-head study comparing Entyvio to AbbVie's Humira, as well as preliminary results of an ongoing post-marketing requirement study for Pfizer's Xeljanz regarding safety are beginning to affect gastroenterologists' perceptions and use of key...

INNATE PHARMA ENROLLS FIRST PATIENT IN IPH4102 TELLOMAK PHASE II STUDY TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the...

Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the...

Dr. Mohammed is a Professor of Cancer Biology at the Department of Comparative Pathobiology, Purdue Center for Cancer Research, and Indiana University School of Medicine. Image Credit: Cannabis Science Cannabis Science, a U.S. company specializing in the development...

--First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GFB-887, a Targeted Podocyte-protective Therapeutic for the treatment of Focal Segmental Glomerulosclerosis, Treatment-resistant Minimal Change Disease and Diabetic Nephropathy--...